Sign up USA
Proactive Investors - Run By Investors For Investors

AcelRx completes human factors study for painkiller DSUVIA

Study marks last step required before new drug application with FDA
pills
The human factors study was recommended by the FDA

AcelRx Pharmaceuticals Inc (Nasdaq:ACRX), a pharmaceutical group that develops therapies for the treatment of acute pain, has finished its human factors study, which was designed to show the effectiveness of its painkiller DSUVIA’s usage directions.

The completion of the human factors study marks the last step required to prepare AcelRx’s DSUVIA’s new drug application, which is set to be resubmitted to the US Food and Drug Administration in the second quarter of this year.

In morning trade, AcelRx shares rose 4.7% to US$2.35.

“This study was the first of our key 2018 milestones outlined on our year-end earnings call,” said Vince Angotti, chief executive of AcelRx, in a statement. “We remain focused on the achievement of each of these key milestones, which we believe will enable 2018 to be a transformational year for AcelRx.”

DSUVIA consists of 30mcg of sufentanil in small tablets, taken under the tongue, which are delivered via a disposable, pre-filled single dose applicator. The drug is intended to be used to manage acute pain in emergency medicine, outpatient surgery and surgeries when only a short stay is required.

The completion of the human factors study was recommended by the FDA after AcelRx submitted recommended changes to the directions accompanying DSUVIA.

View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

Bricklive
December 28 2017
Apparently, at some point in their lives every person in the UK will hold or touch a Lego brick - Parallel is building a business around the famous plastic bricks
Media junkie
February 13 2018
In modern parlance, Ebiquity is making a pivot towards becoming the "world's leading tech-enabled marketing and media analytics consultancy"
Cello
April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use